ABITEC Corporation, an ABF Ingredients company, announced today that it has executed a Memorandum of Understanding (MoU) agreement with Luca AICell Inc. headquartered in Gyeonggido, Republic of Korea. This MoU was established to support foundational research programs of harmonized scientific interests with the objective to advance the utilization of ultra-high purity lipidic chemistries across an ever-expanding array of scientific, medical and pharmaceutical disciplines.
Since the acquisition of Larodan in 2020, the ABITEC-Larodan team of dedicated chemists and scientists are at a pivotal point in the reassessment of our approach to innovation. Dr. Donald Kelemen, Global Business Director for ABITEC states, “It is through visionary collaborations with outstanding global organizations such as Luca AICell that has provided ABITEC the opportunity to expand our focus towards basic science, as opposed to historic short-term commercial drivers.
We believe this directional approach towards innovation is paramount to the development of impactful lipid products and their associated applications to further understand and address the scientific and biological challenges facing the market sectors that we serve today and tomorrow.” Dr. Kelemen further states that “from our initial discussions with the founder of Luca AICell, Professor Nam-Joon Cho, Ph.D., there was an immediate appreciation for the combined synergies that ABITEC-Larodan bring to the table that can hold great promise to further advance and expand the scientific and technology platforms, especially those focused on lipid-based APIs and nano-carrier systems under development at Luca AICell”.
Luca AICell is a bio-platform technology company that has developed a proprietary and state-of-the- art artificial cell membrane technology (LUCA Lipid Bilayer-LLBTM). Using artificial intelligence to optimize their nano-assembly technology, Luca AICell has the capabilities to utilize various types of unique functional lipids, according to their chemical structure, and apply optimal formulation ratios to create artificial cell membranes. Professor Nam-Joon Cho of LUCA AICell, the developer of artificial cell membrane technology, states, “Lipid nanoparticle technology is a drug delivery system that injects various vaccines and active drugs into our body to ensure that the substance is maintained in different physiological environments and protected to reach the target point. Through this joint research collaboration and business partnership (commercialization) with ABITEC, it is not only possible to produce mRNA vaccines, but also possible to establish a standard platform technology that composes a delivery system suitable for the characteristics and administration purpose of various infectious disease vaccines”.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!